Follow LF0 researchXLinkedInSubstackFacebook
tput: No value for $TERM and no -T specified
lf0Research Desk
Menu

Research

Teva Pharmaceutical (TEVA) Stock Analysis & Research

Latest rating
Hold
Latest report
Jul 23, 2026
Reports
1
Sector
Healthcare
All covered stocksHow our ratings performed

Teva Pharmaceutical Industries (TEVA) is a biopharmaceutical company with a large generics franchise alongside innovative medicines, biosimilars, and OTC products. It markets more than 350 generic products in the U.S. and sells branded drugs like AUSTEDO and COPAXONE, operating across 57 markets.

Backtesting dashboard with equity curve and drawdown analysis
Quantitative market report dashboard with factor and risk analysis
SEC filing comparison with highlighted document changes

Most Popular Research

EOSEHOLDJun 22, 2026Eos Energy Enterprises Stock Analysis: EOSE Cash Burn, Revenue Growth & Financing RiskEos Energy Enterprises (EOSE) is rated Hold as rapid Q1 revenue growth is offset by persistent cash burn…SOUNSELLJun 14, 2026SoundHound AI Stock Analysis: Buy or Sell? Margin, Cash Burn & ValuationSoundHound AI (SOUN) carries a sell rating because strong revenue growth has not yet translated into self-funding economics.…AMKRSELLOct 21, 2026Amkor Technology Stock Analysis: AMKR Free Cash Flow, Valuation & Customer ConcentrationAmkor Technology (AMKR) is rated Sell as valuation remains rich while free cash flow is still negative. Customer…NVTSSELLOct 3, 2026Navitas Semiconductor Stock Analysis: Buy or Sell? Valuation & Cash BurnNavitas Semiconductor (NVTS) is rated Sell as the market prices in a turnaround that the latest numbers do…QXOHOLDJun 18, 2026QXO Stock Analysis: Valuation, Margins, Free Cash Flow & LeverageQXO, Inc. (QXO) is rated Hold as its valuation already prices in a recovery that has yet to…PLSELLSep 18, 2026Planet Labs Stock Analysis: Buy or Sell? Valuation, Margin & LeveragePlanet Labs PBC (PL) is a SELL as rapid revenue growth has not yet justified its 15.4x EV/revenue…